ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1368

How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey

Ivan Foeldvari1, Nicola Helmus2 and Suzanne Li3, 1Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 2Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, 3Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ

Meeting: ACR Convergence 2022

Keywords: Pediatric rheumatology, Scleroderma, Localized, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Pediatric scleroderma consists of two diseases, juvenile localized scleroderma (jLS) and juvenile systemic sclerosis (jSSc). While jLS and jSSc share some disease processes, there are major differences in their clinical features and morbidity patterns. Co-existence of LS and SSc has been reported in adults, with a recent adult systematic review reporting a frequency of 2.4-7.4%, and most patients having SSc prior to development of LS1 To explore this issue in pediatric scleroderma, we conducted a survey over the international pediatric rheumatology email board to ask about the co-existence of jLSc and jSSc.

Methods: A 12 question was distributed over the worldwide pediatric rheumatology electronic list-serve. Data was collected in an Excel spread sheet and analyzed using Excel software.

Results: From approximately 800 survey recipients worldwide, physicians from 28 centers responded (27 pediatric rheumatologists, 1 pediatric dermatologist, half were practicing for over 20 years). Respondents followed a median of 12 jLS and 2 jSSc patients over the past 12 months, and a total of 916 jLS and 193 jSSc patients over the past 60 months. Only 7 of the patients had concurrent jLS and jSSc (0.8% of total jLS, 3.6% of total jSSc patients). Four of the patients developed jSSc following onset of jLS, with interval for 3 patients reported as 6 months, 1 year, or 6 years. Among the other 3 coexisting patients, one simultaneously presented with jLS and jSSc, and the pattern for the other two patients was not reported. jLS subtype was generalized morphea (2, one as part of mixed morphea), linear of the trunk/limb (2, one as part of mixed morphea), circumscribed superficial morphea, or mixed morphea. Many of the jLS patients who did not develop jSSc were reported to have features associated with jSSc. Raynaud Phenomenon occurred in 397 patients from 7 centers, for a collective overall frequency of 45%(879 total patients), while nailfoldcapillary changes were reported in 359 patients from 4 centers, for a collective overall frequency of 43% (842 patients). Abnormal pulmonary function or imaging tests were found in 145 from 3 centers, collective overall frequency 24%. Gut involvement including gastroesophageal reflux was found in 534 patients from 9 centers, collective overall frequency 61%.

Conclusion: In this international survey cohort of 916 jLS and 193 jSSc patients, the overall frequency of co-existence of these 2 diseases was low, only 0.8% of the jLSc patients, 3.6% of the jSSc patients. However, many jLS patients were reported to jSSc-associated symptoms including Raynaud Phenomenon. More work is needed to evaluate the features associated with co-existence of these two forms of scleroderma in children.


Disclosures: I. Foeldvari, None; N. Helmus, None; S. Li, Merck/MSD, Wolters Kluwer.

To cite this abstract in AMA style:

Foeldvari I, Helmus N, Li S. How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/how-common-is-the-coexistence-of-juvenile-localized-and-systemic-scleroderma-results-of-a-multination-survey/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-common-is-the-coexistence-of-juvenile-localized-and-systemic-scleroderma-results-of-a-multination-survey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology